Planegg, Germany

Agustin De La Calle


Average Co-Inventor Count = 8.0

ph-index = 2

Forward Citations = 24(Granted Patents)


Location History:

  • Plannegg, DE (2010)
  • Planegg, DE (2007 - 2012)

Company Filing History:


Years Active: 2007-2012

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Agustin De La Calle: Innovator in Cancer Treatment

Introduction

Agustin De La Calle is a prominent inventor based in Planegg, Germany. He has made significant contributions to the field of cancer research, particularly through his innovative work in antibody development. With a total of five patents to his name, De La Calle is recognized for his dedication to advancing medical science.

Latest Patents

One of his latest patents is titled "Antibodies against cancer antigen TMEFF2 and uses thereof." This invention focuses on the identification and generation of antibodies that specifically bind to TMEFF2 proteins, which play a crucial role in cancer progression. The patent outlines the potential use of these antibodies in cancer treatment, providing a promising avenue for therapeutic intervention. Another related patent also addresses methods and compositions for the diagnosis and treatment of cancer, further showcasing his commitment to combating this disease.

Career Highlights

Throughout his career, Agustin De La Calle has worked with notable companies in the biotechnology sector, including Facet Biotech Corporation and PDL Biopharma, Inc. His experience in these organizations has allowed him to collaborate with leading experts and contribute to groundbreaking research in cancer therapies.

Collaborations

De La Calle has collaborated with several professionals in his field, including Vinay Bhaskar and Debbie Law. These partnerships have enhanced his research efforts and facilitated the development of innovative solutions for cancer treatment.

Conclusion

Agustin De La Calle's work in developing antibodies for cancer treatment exemplifies his commitment to innovation in medical science. His patents and collaborations reflect a dedication to improving patient outcomes and advancing the field of oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…